XIG (FHIR Server FHIR Server Version n/a)

FHIR IG Statistics (2750 ms)

Version: All | R2 | R2B | R3 | R4 | R4B | R5 | R6
Authority: All | hl7 | ihe | national
Realm: All | au | be | BNW | br | ca | ch | cl | cr | cz | de | dk | ee | efss | essilux | eu | examples | fi | fr | il | in | it | jp | nl | no | nume | nz | pt | rdsuwearme | sami | se | sl | stt | test | tw | uk | us | uv | vn
View: All | Resource Profiles | Datatype Profiles | Extensions | Logical Models | CodeSystems | ValueSets | ConceptMaps

Resources - All Kinds, Realm US, Authority Hl7

16260 resources

By Version

R2: 52
R2B: 0
R3: 522
R4: 15248
R4B: 0
R5: 438
R6: 0

Package	Version	Identity	Name/Title	Status	Date
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.146	Cancer Stage IV	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.147	Cancer Stage IVA	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.148	Cancer Stage IVB	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.149	Cancer Stage IVC	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.151	Cisplatin Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.153	Vinorelbine Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.154	Gemcitabine Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.155	Docetaxel	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.156	Pemetrexed Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.158	Vinblastine Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.160	ECOG Performance Status	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.161	ECOG Performance Status	active	2020-10
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.162	ECOG Performance Status	active	2022-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.164	Karnofsky Performance Status	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.165	Carboplatin Injectable	active	2020-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.166	Paclitaxel	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.168	Doxorubicin Injectable	active	2022-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.169	Irinotecan Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.179	Bevacizumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.181	Methotrexate	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.184	Breast Cancer	active	2022-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.185	Breast Cancer	active	2023-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.191	Cancer Stage II	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.192	Cancer Stage IIA	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.193	Cancer Stage IIB	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.194	Pertuzumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.196	Ixabepilone Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.197	Goserelin	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.200	Epirubicin Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.202	Ramucirumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.204	Letrozole	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.206	Exemestane	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.209	Fluorouracil	active	2024-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.210	Capecitabine Oral	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.222	Aprepitant Oral	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.223	Fosaprepitant Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.255	Colorectal Cancer	active	2021-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.256	Colorectal Cancer	active	2021-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.257	Colorectal Cancer Chemotherapy	active	2023-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.280	Cancer Stage IA	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.281	Cancer Stage IB	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.286	Cancer Stage IIC	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.291	Positive Result	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.292	Negative Result	active	2015-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.300	Pathological N Stage N1C	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.332	Daunorubicin Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.336	Palonosetron Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.341	External Beam Radiotherapy	active	2024-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.349	Metastatic Cancer	active	2023-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.365	Hospice Care Referral or Admission	active	2025-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.439	T Category	active	2018-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.440	N Category	active	2018-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.441	M Category	active	2018-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.442	TNM Stage Group	active	2018-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.449	Opioids	active	2024-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.492	Pharmacological interventions for depression	active	2024-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.535	Ovarian Cancer	active	2023-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.536	Ovarian Cancer	active	2023-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.537	Fallopian Tube Cancer	active	2022-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.539	Fallopian Tube Cancer	active	2022-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.541	Peritoneal Cancer	active	2022-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.542	Peritoneal Cancer	active	2023-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.547	Cancer Stage 1C	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.555	Gender Female	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.556	Gender Male	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.557	Pathological N Stage N3a	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.558	Pathological N Stage N3b	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.560	Rolapitant Oral	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.599	Obinutuzumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.600	Ofatumumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.602	Neurokinin 1 Receptor Antagonist	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.604	Serotonin Receptor Antagonist	active	2025-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.61	Cetuximab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.63	Panitumumab Injectable	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.81	Palonosetron Oral	active	2024-12
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.88	Lung Cancer	active	2015-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.89	Lung Cancer	active	2023-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.95	M Stage M0	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.97	Pathological M Stage M1	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.98	Pathological M Stage M1a	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.99	Pathological M Stage M1b	active	2024-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.5	Most/Moderately Effective Contraceptive Procedures	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1121.6	Most/Moderately Effective Contraceptive SNOMED Findings	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.1	Schedule IV Benzodiazepines	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1125.7	PROMIS Depression Assessment	active	2023-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.11	Sleep Apnea	active	2018-05
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.12	Toxic Megacolon in adults	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.13	Septic Shock due to C. Diff	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.15	Body Temperature	active	2022-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.16	Diarrhea Potentially due to CDI	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.17	Abdominal Distension	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.18	Vomiting potentially due to CDI	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.19	Ileus due to infection	active	2019-04
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.20	Clostridium difficile infection	active	2019-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.3	Radiation Therapy Indicators from CPT	active	2017-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.4	Diagnostic Radiology Surrounding Face and Sinus	active	2017-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.5	Ear Surgery Affecting the Tympanic Membrane	active	2017-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.6	Allergic Rhinitis Immunotherapy	active	2017-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.8	Radiology to Head and Sinus	active	2017-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1130.9	Immunotherapy For Allergic Rhinitis	active	2022-03
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1136.63	Aortic Dissection or Ruptured Aortic Aneurysm	active	2024-07
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.564	CABG or PCI Procedure	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.565	CABG or PCI Procedure	active	2025-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1138.566	CABG or PCI Procedure	active	2018-08
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.1	C2S Alcohol Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.11	C2S Amphetamine Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.12	C2S Cannabis Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.13	C2S Cannabis Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.14	C2S Cannabis Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.15	C2S Cannabis Use DIsorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.16	C2S Cocaine Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.17	C2S Cocaine Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.18	C2S Cocaine Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.19	C2S Hallucinogens	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.2	C2S Alcohol Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.20	C2S Hallucinogens	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.21	C2S Hallucinogens	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.22	C2S Hallucinogens	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.23	C2S HIV/AIDS Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.24	C2S HIV/AIDS Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.25	C2S HIV/AIDS Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.26	C2S HIV/AIDS Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.27	C2S HIV/AIDS Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.28	C2S Inhalants	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.29	C2S Inhalants	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.3	C2S Alcohol Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.30	C2S Inhalants	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.32	C2S Mental Health Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.33	C2S Mental Health Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.34	C2S Mental Health Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.35	C2S Mental Health Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.36	C2S Mental Health Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.38	C2S Opioids	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.39	C2S Opioids	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.4	C2S Alcohol Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.40	C2S Opioids	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.42	C2S Opioids	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.43	C2S Other Psychoactive Substance Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.44	C2S Other Psychoactive Substance Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.45	C2S Other Psychoactive Substance Use Disorder	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.46	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.47	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.48	C2S Sedative Hypnotic, or anxiolytic related disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.49	C2S Sexuality and reproductive health information sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.5	C2S Alcohol Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.51	C2S Tobacco Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.52	C2S Tobacco Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.53	C2S Tobacco Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.54	C2S Tobacco Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.55	C2S Substance Use Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.56	C2S Substance Use Information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.58	C2S Sensitive Categories	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.59	C2S Opioids	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.6	C2S Amphetamine Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.60	C2S HIV/AIDS information Sensitivity	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.65	Test C2S Alcohol Use Disorders	active	2019-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.67	Test C2S HIV/AIDS Information Sensitivity	active	2019-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.7	C2S Amphetamine Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.8	C2S Amphetamine Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1142.9	C2S Amphetamine Use Disorders	active	2016-09
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.10	Diphtheria (Tests for Corynebacterium diphtheriae by Culture and Identification Method)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1002	Tuberculosis (Tests for Mycobacterium species by Culture and Identification Method)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1012	S. Typhi Infection (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1016	S. Paratyphi Infection (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1017	S. Typhi Infection (Tests for S. Typhi by Culture and Identification Method)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1021	Dark Urine (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1022	Acute Onset [Qualifier Value] (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1024	Acute Viral Hepatitis (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1027	Sepsis [Septicemia] [Bacterial] [Unspecified Organism] (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1029	Listeriosis [Listeria species] (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1030	Meningitis [Unspecified Cause] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1032	Encephalitis [Unspecified Cause] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1033	Encephalitis [Unspecified Cause] (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1035	Indeterminate or Equivocal Lab Result Value	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1037	Smoking Status [Current Nonsmoker] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1040	Organisms (Tests by Unspecified Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1041	Organisms (Tests by Culture and Identification)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1044	Candida auris Infection (Tests for Candida auris by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1045	Candida auris Infection (Tests for Candida auris Nucleic Acid)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1047	Parkinson’s disease (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1048	Parkinson’s disease (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1049	Parkinsonism [Secondary] (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1050	Parkinsonism [Secondary] (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1053	Carbidopa Levodopa Combination (RXNORM)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1065	Consciousness [Decreased Level] (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1071	Drug Use [IV Evidence] (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1072	Miosis (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1076	Opioid Overdose and Poisoning (Tests for Opioids [Quantitative])	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1077	Poisoning or Overdose by Other Opioids (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1078	Opioid Overdose and Poisoning (Naloxone) (RxNorm)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1083	Rash [Pustular Vesicular] (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1084	Salivary Gland Swelling [Unspecified Cause] (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1090	Syphilis [Congenital] (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1091	Cataracts [Nonspecific]/Congenital glaucoma [Unspecified Cause] (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1092	Congenital heart disease (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1093	Hearing impairment (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1095	Microcephaly (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1096	Developmental delay (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1099	Congenital heart disease (ICD10CM)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1100	Hearing impairment (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1104	Developmental delay (ICD10CM)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1106	Listeriosis (Tests for Listeria monocytogenes Nucleic Acid in Specimen from Normally Sterile Site)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.112	Tetanus (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1123	COVID_19 (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1124	COVID_19 (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1130	Tickborne Relapsing Fever (Tests for Borrelia hermsii/miyamotoi/parkerii/turicatae Nucleic Acid)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1131	Lyme Disease (Tests for Borrelia afzelii/garinii IgG Antibody by Immunoassay	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1138	Staphylococcus Aureus (Tests by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1139	VISA/VRSA (Tests for Vancomycin Resistance Gene)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1142	COVID_19 (Tests for SARS_CoV_2 Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1143	COVID_19 (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1145	Resistant Lab Result Value	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1148	Tests for Vancomycin Susceptibility [Ord]	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1149	Proteinuria (Tests for Total Protein in 24H Urine)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.115	Mumps (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1150	Thrombocytopenia (Tests for Platelets [#/volume] in Blood)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1156	Staphylococcus aureus (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1158	COVID_19 (Tests for SARS_CoV_2 Antigen)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1169	Chikungunya Virus Disease (Tests for Chikungunya virus Nucleic Acid)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.117	Mumps (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1180	Chikungunya Virus Disease (Tests for Chikungunya Virus Antibody [Quantitative])	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1186	Eastern Equine Encephalitis Virus Disease (Tests for Eastern Equine Encephalitis Virus Antibody [Qualitative])	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1188	Western Equine Encephalitis Virus Disease (Tests for Western Equine Encephalitis Virus Antibody [Qualitative])	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1189	California Serogroup Virus Diseases (Tests for California Serogroup Virus Antibody [Qualitative])	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1196	Anthrax (Tests for Bacillus cereus by Culture and Identification Method)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1197	Cervical Lymphadenitis (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1207	CRE (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1210	Enterobacter spp., E. coli, or Klebsiella spp. (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1212	Enterobacteriaceae species [Carbapenem Resistant] (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1213	NU_Enterobacteriaceae [Carbapenemase Producing] (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1214	Carbapenemase resistance mechanism (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1215	Tests for carbapenemase production	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1216	Tests for carbapenemase resistance mechanism	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1217	Tests for carbapenem susceptibility [Meropenem, imipenem, and doripenem]	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1218	Tests for carbapenem susceptibility [Ertapenem]	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1219	Tests for Enterobacter spp., E. coli, or Klebsiella spp. by Culture and Identification Method	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1220	NU_Tests for Enterobacteriaceae species by Culture and Identification Method	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1224	Therapeutic Response to Medication [Improved]	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1225	Altered Mental Status (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1230	Eschar (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1231	Hypotension (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1233	Localized Edema (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1234	Localized Edema (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1237	Tachycardia (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1238	Tachycardia (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1239	RCKMS Conditions (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.124	Poliomyelitis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1240	Maternal Condition Puerperium (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1242	Non pestis Yersiniosis Infection (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1244	Blastomycosis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1246	Blastomycosis (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1249	Blastomycosis (Tests for Blastomyces species by Culture and Identification Method)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1250	Non pestis Yersiniosis Infection (Tests for Yersinia non pestis species Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1251	Blastomycosis (Tests for Blastomyces species Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1252	Blastomycosis (Tests for Blastomyces species Antibody)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1253	Blastomycosis (Tests for Blastomyces species Antigen)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1265	Fatigue (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1269	Tuberculosis [Latent Infection] (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1274	Histoplasmosis (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1275	Histoplasmosis (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1281	Histoplasmosis (Tests for Histoplasma capsulatum H band or M band Antibody)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1294	Abscess [Liver, Lung, Spleen, Prostate, or Brain] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1295	Seizure [Unspecified Cause] (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1298	Abscess [Liver, Lung, Spleen, Prostate, or Brain] (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1299	Seizure [Unspecified Cause] (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.130	Influenza (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1304	Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species in Extrapulmonary Specimen by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1305	Mycobacteria_Infection_NonTB_ExPulm (Tests for Mycobacterium species Nucleic Acid in Extrapulmonary Specimen)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1306	Body Temperature (Vital Sign)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1307	Respiratory Rate (Vital Sign)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1309	RSV (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1310	RSV (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1312	RSV (Tests for RSV Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1314	Wheezing (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1317	Bronchiolitis (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1325	Tobacco Use and Exposure (Social History)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1330	Tobacco Smoking Status [Current] (Social History) (LOINC)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1335	Hospitalized [Inpatient] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1336	Creutzfeldt Jakob Disease (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1337	Variant Creutzfeldt Jakob Disease (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1340	Prion Disease (Tests for 14_3_3 Protein)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1341	Prion Disease (Tests for Abnormal Prion Protein)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1349	Cerebrospinal Fluid (Specimen Type) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.135	Chronic Hepatitis B Virus Infection (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1350	Endocervical (Specimen Type) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1351	Tissue (Specimen Type) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1352	Specimen from a Normally Sterile Site (Specimen Type)(SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1353	Urethral Swab (Specimen Type) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1355	Wound (Specimen Type) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1359	Hepatitis E (Tests for hepatitis E virus IgM Antibody)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.136	Invasive Pneumococcal Disease (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1360	Hepatitis E (Tests for hepatitis E virus Antibody)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1363	Epiglottitis (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1364	Organisms (Tests by Microscopic Observation by Gram Stain)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1369	Serum (Specimen Type) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1378	Tests for Mycobacterium species Nucleic Acid in Unspecified XXX Specimen	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1379	Fish Poisoning (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1388	Occupational Asthma (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1389	Asthma (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1390	Asthma (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1391	Respiratory Condition, due to inhalation of chemicals, gases, fumes or vapors (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1393	WRA (Occupational Exposure to Potential Asthma Inducing Risk Factor) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1400	Colorado tick fever (Tests for Colorado Tick Fever Virus Antibody [Qualitative])	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1402	Cancer [Malignant Neoplasms] (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1403	Cancer [Benign or Borderline CNS Tumors] (Disorders) (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1404	Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1405	Cancer [Unspecified Skin Cancer, Benign Carcinoid Tumor, in situ Cervical Cancer, Intraepithelial Neoplasia, History Cancer, Complication of Cancer or Treatment] (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1407	Cancer [Malignant Neoplasms] (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1409	COVID_19 (Tests for SARS_CoV_2 Genomic Sequence)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1418	Alpha gal syndrome (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1420	Alpha gal syndrome (Tests for Alpha gal IgE Antibody [Quantitative])	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1422	Ptosis of Eyelid [Unspecified Cause] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1423	Ptosis of Eyelid [Unspecified Cause] (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1424	Constipation [Unspecified Cause] (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1426	Intubation [Respiratory Tract] (Procedure) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1430	Infant Botulism (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1446	Viral Hemorrhagic Fever [Suspected] (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1447	MRSA (Disorders (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1449	Staphylococcus aureus infection (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.145	Varicella (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1450	Staphylococcus aureus infection (Disorders) (ICD10CM)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1452	MRSA (Tests by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1453	MRSA (Tests for Methicillin Resistance Gene)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1454	Staphylococcus aureus (Tests for Staph aureus Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1458	Tests for Cefoxitin Susceptibility [OrdQn]	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1459	Organisms (Tests in Blood by Culture and Identification)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1460	Bacteria (Tests in Blood by Culture and Identification Method)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1461	Organisms (Tests in Specimen from Normally Sterile Site by Culture and Identification)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1462	Staphylococcus aureus (Tests for Staph aureus Nucleic Acid in Blood)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1463	VRE (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1464	VRE (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1465	VRE (Tests by Culture and Identification Method)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1466	Enterococcus species (Tests by Culture and Identification Method)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1468	Enterococcus gallinarum or E. casseliflavus/E. flavescens (Organism or Substance in Lab Results)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1469	Enterococcus faecium or E. faecalis (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1470	Enterococcus species (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1471	Amebiasis (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1473	Amebiasis (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1476	Amebiasis (Tests for Entamoeba histolytica Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1482	Norovirus (Tests for Norovirus Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1485	Norovirus (Organism or Substance in Lab Results)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1487	Clostridioides difficile infection (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1491	C. diff infection (Tests for C diff Toxin Nucleic Acid)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1492	C. diff infection (Tests for C diff Toxin Nucleic Acid in Stool)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1505	Acanthamoeba Disease [Keratitis] (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1507	Arsenic Exposure and Toxicity (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1509	Arsenic Exposure and Toxicity (Tests for Arsenic [Quantitative] in Unspecified Specimen)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1513	Urine (Specimen Type) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1514	Mercury Exposure and Toxicity (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1515	Cryptococcosis (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1516	Cryptococcosis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1520	Cryptococcosis (Tests for Cryptococcus species by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1523	Cryptococcosis (Tests for Cryptococcus species Nucleic Acid)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1524	Cryptococcosis (Tests for Cryptococcus species Antigen)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1525	Mercury Exposure and Toxicity (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1528	Mercury Exposure and Toxicity (Tests for Mercury [Quantitative] in Unspecified Specimen)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1532	Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1533	Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1534	Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1538	Drug Overdose and Poisoning [Non opioid] [Other Drug] (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.154	Hepatitis C Virus Infection (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1540	Drug Overdose and Poisoning [Non opioid] [CNS Stimulant] (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1541	Drug Overdose and Poisoning [Non opioid] [CNS Depressant] (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1542	Drug Overdose and Poisoning [Non opioid] [Hallucinogen] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1543	Drug Overdose and Poisoning [Non opioid] [Cannabinoid] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1544	Drug Overdose and Poisoning [Non opioid] [Analgesic] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1545	Drug Overdose and Poisoning [Non opioid] [Other Drug] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1546	Drug Overdose and Poisoning [Non opioid] (Organism or Substance in Lab Results)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1551	Meningitis (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1552	Bacterial Meningitis (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1553	Fungal Meningitis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1554	Parasitic Meningitis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1555	Bacterial Meningitis (Disorders) (ICD10CM)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1559	Photophobia (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1562	Bacteria [Causing Meningitis] (Organism or Substance in Lab Results)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1563	Fungi [Causing Meningitis and Encephalitis] (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1564	Viruses [Causing Meningitis] (Organism or Substance in Lab Results)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1565	Viruses [Causing Meningitis] (Tests for Nucleic Acid)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1566	Viruses [Causing Meningitis] (Tests for Nucleic Acid in Cerebrospinal Fluid)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1567	Bacteria [Causing Meningitis] (Tests by Culture and Identification Method)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1574	Invasive Group B Streptococcus (Disorders) (ICD10CM))	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1577	Group A Streptococcus (Tests for Group A Strep by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1578	Group B Streptococcus (Tests for Group B Strep by Culture and Identification Method)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1580	Animal Bite [Dog] (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1581	Animal Bite [Mammal, Excluding Dogs] (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1582	Animal Bite [Excluding Mammals] (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1584	Animal Bite [Unspecified Animal] (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1585	Animal Bite [Dog] (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1586	Animal Bite [Mammal, Excluding Dogs] (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1587	Animal Bite [Excluding Mammals] (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1588	Cadmium Exposure and Toxicity (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1594	HIV Infection (ARV Nucleoside Reverse Transcriptase Inhibitors [NRTIs]) (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1595	HIV Infection (ARV Non nucleoside Reverse Transcriptase Inhibitors [NNRTIs]) (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1597	HIV Infection (ARV Combination Treatment for HIV) (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1598	HIV Infection (ARV Protease Inhibitors [PIs]) (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1600	HIV Infection (ARV Integrase Strand Transfer Inhibitors [INSTIs]) (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1604	Vaccine Adverse Event (Disorders) (ICD10CM)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1605	Vaccine Adverse Event (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1606	Vaccinia disease or adverse event (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.161	Vibriosis (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1612	Blepharitis [Unspecified Cause] (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1613	Keratitis [Unspecified Cause] (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1614	Keratitis [Unspecified Cause] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1618	Smallpox Vaccine (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1620	Anaphylaxis [Unspecified Cause] (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1626	Thrombocytopenic Purpura [Unspecified Cause] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1634	Sofosbuvir Velpatasvir Combination (RXNORM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1640	Typhus Fever (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1641	Typhus Fever (Tests for Rickettsia Typhus Group IgG Antibody)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1642	Typhus Fever (Tests for Rickettsia Typhus Group IgM Antibody)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1643	Typhus Fever (Tests for Rickettsia Typhus Fever Group IgG Antibody [Quantitative] by Immunofluorescence)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1651	Chagas Disease (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1654	Chagas Disease (Tests for Trypanosoma cruzi Antibody)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1661	Cervical lymphadenopathy [Unspecified Cause] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1662	Conjunctival injection (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1663	Drying of lips (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1667	Edema of hands or feet (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1676	Tests for Acinetobacter baumannii Nucleic Acid	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1677	Tests for Pseudomonas aeruginosa by Culture and Identification Method	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1678	Tests for Pseudomonas aeruginosa Nucleic Acid	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1679	Pseudomonas aeruginosa (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1687	NU_Gunshot Wound (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1688	NU_Gunshot Wound (Disorders) (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.169	Gonorrhea [Neisseria gonorrhoeae] (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.170	Chlamydia trachomatis Infection (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1700	Encephalitis [Viral] (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1702	Encephalitis [Parasitic] (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1712	Bacteria [Causing Encephalitis] (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1714	Parasites [Causing Encephalitis] (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1715	Viruses [Causing Encephalitis] (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1716	Drowning and Submersion (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1717	Drowning and Submersion (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1718	Motor Vehicle Injury (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1719	Motor Vehicle Injury (Disorders) (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1720	Enterovirus Infection [Non polio] (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1721	Enterovirus Infection [Non polio] (Disorders) (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1722	Enterovirus Infection [Non polio] (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1723	Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus by Culture and Identification Method)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1725	Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus Nucleic Acid)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1726	Enterovirus Infection [Non polio] (Tests for Non Polio Enterovirus in Cerebrospinal Fluid Nucleic Acid)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1735	Clostridium perfringens Infection (Tests for C perfringens by Culture and Identification Method)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1739	Head Injury (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1740	Head Injury (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1742	Brain Injury [Traumatic] (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1745	Rotavirus Disease (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1746	Rotavirus Disease (Tests for Rotavirus Nucleic Acid)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1748	Chemical Pneumonitis (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1749	Chemical Pneumonitis (Disorders) (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1753	Staphylococcal Enterotoxin B Poisoning (Tests for Staph aureus Enterotoxin B Nucleic Acid)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1755	Vomitus (Specimen Type) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1758	Asbestosis (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.176	West Nile Virus Infection (Disorders) (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1763	Byssinosis (Disorders) (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1769	Farmers Lung (Tests for Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1772	Farmers Lung (Aspergillus fumigatus, Saccharopolyspora rectivirgula, or Thermoactinomyces vulgaris Antibody in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1773	CLABSI (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1775	Ophthalmia neonatorum (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1778	Genital herpes (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1779	Genital herpes (Disorders) (ICD10CM)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1781	Herpes (Tests for Herpes simplex virus Nucleic Acid)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1785	Elevated liver enzyme (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1786	Elevated liver enzyme (ICD10CM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1788	Typhus Fever (Tests for Rickettsia Typhus Fever Group IgM Antibody [Quantitative] by Immunofluorescence)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1789	Granuloma Inguinale (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1791	Ulcer [Genital, Perineal, or Perianal Area] (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1792	Ulcer [Genital, Perineal, or Perianal Area] (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1797	Bronchial Wash (Specimen Type) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1800	Nontuberculous Mycobacteria Infection, Pulmonary (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1803	Bacteria (Tests in Sputum Specimen by Culture and Identification Method)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.181	Coccidioidomycosis (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1819	Louseborne relapsing fever (Tests for Borrelia species)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1820	Louseborne relapsing fever (Tests for Borrelia species in Blood)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1823	Borrelia species (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1824	Spirochetes (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1829	Polyarthritis [Unspecified Cause] (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1835	Rheumatoid nodules (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1842	Ventilator associated event (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1844	Leishmaniasis (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1846	Leishmaniasis (Tests for Leishmania species Nucleic Acid)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1847	Leishmaniasis (Tests for Leishmania species Antibody)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1848	Leishmania species (Tests by Microscopic Observation in Tissue)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.185	Brucellosis (Disorders) (SNOMED)	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1864	Taeniasis (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1866	Taeniasis (Organism or Substance in Lab Results)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.187	Dengue Virus Infection (Disorders) (SNOMED)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1875	Cysticercosis (Tests for Taenia solium Antibody)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1878	Surgical Site Infection (Disorders) (SNOMED)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1880	Tests for Enterobacter spp., E. coli, or Klebsiella spp. Nucleic Acid	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1881	NU_Tests for Enterobacteriaceae species Nucleic Acid	active	2024-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1882	Carbapenemase production (Organism or Substance in Lab Results)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1892	Toxoplasmosis (Disorders) (SNOMED)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1893	Toxoplasmosis (Disorders) (ICD10CM)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1895	Toxoplasmosis (Organism or Substance in Lab Results)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1897	Toxoplasmosis (Tests by Microscopic Observation)	active	2023-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1898	Toxoplasmosis (Tests for Toxoplasma gondii Nucleic Acid)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1901	Toxoplasmosis (Tests for Toxoplasma gondii Antibody)	active	2024-06
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1902	Orthopox (Disorders) (SNOMED)	active	2025-02
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1908	Organisms (Tests by Electron Microscopic Observation)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1912	Penicillin G [Aqueous Crystalline] [Injectable] (RXNORM)	active	2023-01
us.nlm.vsac	R4	http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1146.1913	Penicillin G [Procaine] [Injectable] (RXNORM)	active	2025-02

XIG built as of 22 Jun 2025. Found 77205 resources in 1238 packages.